Pulmatrix Competitors and Similar CompaniesClear all

Pulmatrix's competitors and similar companies include Ipsen, Vertex Pharmaceuticals and CSL Behring.

	Pulmatrix Pulmatrix develops inhaled therapies for the treatment, prevention, and transmission of infectious and progressive respiratory diseases.	Ipsen Ipsen is a biopharmaceutical company.	Vertex Pharmaceuticals Vertex Pharmaceuticals is a biotechnology company that focuses on discovering, developing, and producing medicines.	CSL Behring CSL Behring is a provider of life-saving medicines.
Founding Date	Founding Date 2003	Founding Date 1929	Founding Date 1989	Founding Date 1904
Type	Type Public	Type Public	Type Public	Type Subsidiary
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma
Locations	Locations Lexington, US HQ	Locations Boulogne-Billancourt, FR HQ Algiers, DZ South Yarra, AU Wien, AT Merelbeke, BE São Paulo, BR Mississauga, CA see more	Locations Boston, US HQ St Leonards, AU Wien, AT Bruxelles, BE São Paulo, BR Toronto, CA Praha, CZ see more	Locations King of Prussia, US HQ Broadmeadows, AU Parkville, AU Parkville, AU Wien, AT Mechelen, BE see more
Employees	Employees 228% decrease	Employees 5,358	Employees 5,40013% increase	Employees 7,5692% decrease
Valuation ($)	Valuation ($) 8 m	Valuation ($) 10.2 b	Valuation ($) 121.4 b	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) €3.7b (FY, 2025)	Revenue (est.) $12b (FY, 2025)	Revenue (est.) $7.9b (FY, 2020)
Cost of goods	Cost of goods N/A	Cost of goods €659.1m (FY, 2025)	Cost of goods $1.7b (FY, 2025)	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit €3.3b (FY, 2025)	Gross profit $10.4b (FY, 2025)	Gross profit $4.5b (FY, 2020)
Net income	Net income ($5.2m) (FY, 2025)	Net income €445.1m (FY, 2025)	Net income N/A	Net income N/A
Funding
Total funding raised	Total funding raised $ 47.7m	Total funding raised N/A	Total funding raised $ 2.4m	Total funding raised N/A